- Home
- DMF vs BMEA Comparison
DMF vs BMEA Comparison
Compare DMF & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMF
- BMEA
- Stock Information
- Founded
- DMF 1988
- BMEA 2017
- Country
- DMF United States
- BMEA United States
- Employees
- DMF N/A
- BMEA N/A
- Industry
- DMF Finance/Investors Services
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- DMF Finance
- BMEA Health Care
- Exchange
- DMF Nasdaq
- BMEA Nasdaq
- Market Cap
- DMF 152.2M
- BMEA 125.4M
- IPO Year
- DMF N/A
- BMEA 2021
- Fundamental
- Price
- DMF $7.26
- BMEA $2.04
- Analyst Decision
- DMF
- BMEA Buy
- Analyst Count
- DMF 0
- BMEA 12
- Target Price
- DMF N/A
- BMEA $28.45
- AVG Volume (30 Days)
- DMF 60.7K
- BMEA 689.2K
- Earning Date
- DMF 01-01-0001
- BMEA 05-01-2025
- Dividend Yield
- DMF 2.66%
- BMEA N/A
- EPS Growth
- DMF N/A
- BMEA N/A
- EPS
- DMF 0.15
- BMEA N/A
- Revenue
- DMF N/A
- BMEA N/A
- Revenue This Year
- DMF N/A
- BMEA N/A
- Revenue Next Year
- DMF N/A
- BMEA N/A
- P/E Ratio
- DMF $45.13
- BMEA N/A
- Revenue Growth
- DMF N/A
- BMEA N/A
- 52 Week Low
- DMF $5.37
- BMEA $1.87
- 52 Week High
- DMF $6.79
- BMEA $14.43
- Technical
- Relative Strength Index (RSI)
- DMF 58.25
- BMEA 28.24
- Support Level
- DMF $7.13
- BMEA $1.87
- Resistance Level
- DMF $7.29
- BMEA $2.29
- Average True Range (ATR)
- DMF 0.06
- BMEA 0.23
- MACD
- DMF -0.00
- BMEA -0.03
- Stochastic Oscillator
- DMF 76.00
- BMEA 1.23
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.